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To the Editor:—Peripheral arterial disease (PAD) remains an
under-treated disease1, and information about risk factors and
prognosis is poorly disseminated in the population2. Neverthe-
less, PAD and coronary artery disease (CAD) patients share the
same risk factors, and risks of future cardiovascular events in
PAD patients are comparable with those in CAD patients3.
Depression may adversely impact prognosis in CAD patients4,
but little is known about depression and prognosis in PAD.
Therefore, we read with great interest the work of Cherr and
colleagues5 on the relation between psychological factors and
cardiovascular events in PAD. Their study generated interest-
ing findings, but there are also a number of issues we would
like to address here.
First, the screening method the authors used probably led
to an overestimation of depression rates. The General Health
Questionnaire is not a depression scale, but rather was
developed to assess non-specific psychological distress in
community samples6, and a higher cut-off score (≥8) has been
recommended to screen for depressive symptoms in patients
with chronic somatic disease7.
Second, 80% of depressed patients received antidepressant
therapy. Analyses were not adjusted for type of antidepressant,
while studies warn against the use tricyclic antidepressants in
cardiovascular populations because they are associated with
an increased risk of myocardial infarction8,9. Therefore, we
cannot rule out the influence of antidepressant use on adverse
outcomes in depressed patients.
Finally, in the adjusted analyses, only a rough parameter of
disease severity was included (indication for intervention).
Table 2 shows us that the group that underwent revascular-
ization was very heterogeneous in terms of disease severity;
indication for intervention ranged from claudication to critical
leg ischemia and gangrene or tissue loss. It would have been
more appropriate to include the lowest ankle-brachial index in
the adjusted analyses due to its strong prognostic value for
adverse cardiovascular events in PAD10. Likewise, in CAD, the
relation between depression and increased risk of mortality
seems to be confounded by cardiac disease severity or left
ventricular dysfunction11. Future studies examining the link
between psychological factors and prognosis in PAD need to
take into account reliable indices of disease severity.
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